Full-Time

Principal Software Engineer

Posted on 6/29/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
Software Engineering (2)
,
Required Skills
Python
JavaScript
React.js
NoSQL
Redux.js
SQL
TypeScript
AWS
Elasticsearch
REST APIs
Databricks
Requirements
  • Master’s degree in computer science & engineering preferred with 12-15 years of software development experience OR
  • Bachelor’s degree in computer science & engineering preferred with 11-15 years of software development experience
  • Hands on experience with various cloud services, understand pros and cons of various cloud service in well architected cloud design principles
  • Hands on experience with Full Stack software development. Proficient in programming language React Framework Redux ,RESTful API Development ,Swagger / OpenAPI , TypeScript, Fast Python , Java Script, SQL/NoSQL , Databricks/RDS
  • Strong problem solving, analytical skills; Ability to learn quickly; Excellent communication and interpersonal skills
Responsibilities
  • Lead the design and development of enterprise-wide intelligent search solutions
  • Architect and scale AI-enhanced search platforms
  • Mentor engineers, set standards, and drive the technical vision
  • Define the roadmap for Products
  • Work closely with Development teams and act as a bridge between Product owners and Development teams
  • Build and integrate information systems to meet the companys needs
  • Assess the systems architecture currently in place and recommend solutions to improve it
  • Design and build robust, scalable, and intelligent search infrastructure using Elasticsearch, OpenSearch, Solr, or vector-based search technologies
  • Set technical direction, best practices, and coding standards for search engineering
  • Review designs, mentor senior and mid-level engineers, and champion architecture decisions
  • Own performance, scalability, observability, and reliability of search services in production
  • Resolve technical problems as they arise
  • Provide technical guidance and mentorship to junior developers
  • Research current and emerging technologies and propose changes
  • Inform stakeholders about problems with current technical solutions
  • Assess the business impact of technical choices
  • Provide updates to stakeholders on product development processes, costs, and budgets
  • Work closely with Information Technology professionals to ensure hardware is available for projects
  • Work closely with project management teams to monitor progress of initiatives
  • Account for possible project challenges on constraints including risks, time, resources and scope
  • Take ownership of complex software projects from conception to deployment
  • Participate in both front-end and back-end development using cloud technology
  • Develop innovative solutions using generative AI technologies
  • Define and implement robust software architectures on the cloud, AWS preferred
  • Conduct code reviews to ensure code quality and alignment to best practices
  • Create and maintain documentation on software architecture, design, deployment, disaster recovery, and operations
  • Identify and resolve technical challenges effectively
  • Stay updated with the latest trends and advancements
  • Work closely with product team, business team, and other key partners
Desired Qualifications
  • Proficiency in multiple programming languages (e.g., Python, Java, JavaScript UI/UX , React /Redux/Typescript)
  • Experienced with API integration, serverless, microservices architecture
  • Experienced with Fast Pythons API
  • Understanding of different architectural patterns and how to design scalable and maintainable systems
  • Expertise in designing and architecting complex software systems
  • Familiarity with fundamental principles like SOLID, DRY, and KISS
  • A strong foundation in data structures and algorithms
  • Experienced with AWS /Azure Platform, Building and deploying the code
  • Experience in Posgres SQL /Mongo DB SQL database, vector database for large language models, Databricks or RDS
  • Experience with website development and understanding of website localization processes
  • Experience with DevOps CICD build and deployment pipeline
  • Experience in Agile software development methodologies
  • Contributing to the overall strategic direction of the software development process
  • Experience in API and End to End testing as part of Test Driven Development

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE